Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Antineoplastic Combined Chemotherapy Protocols | 19 | 2023 | 329 | 1.850 |
Why?
|
Leukemia, Myeloid, Acute | 5 | 2021 | 45 | 1.250 |
Why?
|
Lymphoma, Non-Hodgkin | 8 | 2019 | 42 | 1.240 |
Why?
|
Arabinonucleosides | 4 | 2021 | 6 | 1.010 |
Why?
|
Lymphoma, Large B-Cell, Diffuse | 6 | 2019 | 24 | 1.000 |
Why?
|
Lymphoma | 3 | 2023 | 44 | 1.000 |
Why?
|
Central Nervous System Neoplasms | 3 | 2023 | 13 | 0.980 |
Why?
|
Antibodies, Monoclonal | 8 | 2011 | 270 | 0.980 |
Why?
|
Rituximab | 16 | 2023 | 54 | 0.970 |
Why?
|
Antineoplastic Agents | 5 | 2022 | 252 | 0.790 |
Why?
|
Antibodies, Monoclonal, Murine-Derived | 11 | 2017 | 38 | 0.790 |
Why?
|
Adenine Nucleotides | 2 | 2010 | 2 | 0.720 |
Why?
|
Burkitt Lymphoma | 3 | 2021 | 7 | 0.580 |
Why?
|
Paraproteinemias | 2 | 2019 | 5 | 0.560 |
Why?
|
Insulin-Like Growth Factor Binding Proteins | 1 | 2015 | 11 | 0.510 |
Why?
|
Insulin-Like Growth Factor I | 1 | 2015 | 58 | 0.490 |
Why?
|
Middle Aged | 25 | 2023 | 9963 | 0.470 |
Why?
|
Treatment Outcome | 18 | 2021 | 3561 | 0.460 |
Why?
|
Adult | 21 | 2021 | 8748 | 0.460 |
Why?
|
Humans | 43 | 2023 | 29853 | 0.450 |
Why?
|
Aged | 22 | 2023 | 9621 | 0.430 |
Why?
|
Male | 25 | 2022 | 15871 | 0.410 |
Why?
|
Cyclophosphamide | 9 | 2021 | 56 | 0.400 |
Why?
|
Necrobiotic Xanthogranuloma | 1 | 2011 | 1 | 0.400 |
Why?
|
Plasma Cells | 1 | 2011 | 8 | 0.400 |
Why?
|
Mediastinum | 1 | 2011 | 6 | 0.400 |
Why?
|
Lymphoma, Mantle-Cell | 1 | 2011 | 6 | 0.390 |
Why?
|
Leukemia, Lymphocytic, Chronic, B-Cell | 3 | 2022 | 18 | 0.370 |
Why?
|
Doxorubicin | 7 | 2021 | 70 | 0.360 |
Why?
|
Female | 26 | 2021 | 16429 | 0.350 |
Why?
|
Arsenicals | 2 | 2007 | 9 | 0.350 |
Why?
|
Oxides | 2 | 2007 | 13 | 0.350 |
Why?
|
Cranial Irradiation | 2 | 2007 | 13 | 0.350 |
Why?
|
Aged, 80 and over | 11 | 2023 | 4930 | 0.340 |
Why?
|
Vincristine | 7 | 2019 | 27 | 0.340 |
Why?
|
Prednisone | 7 | 2019 | 68 | 0.330 |
Why?
|
Lymphohistiocytosis, Hemophagocytic | 1 | 2008 | 8 | 0.320 |
Why?
|
Cachexia | 2 | 2019 | 11 | 0.310 |
Why?
|
Disease-Free Survival | 7 | 2021 | 191 | 0.300 |
Why?
|
Kaplan-Meier Estimate | 5 | 2021 | 177 | 0.300 |
Why?
|
Leukemia, Myelomonocytic, Acute | 1 | 2007 | 1 | 0.290 |
Why?
|
Sarcoma, Myeloid | 1 | 2007 | 4 | 0.290 |
Why?
|
Ear Neoplasms | 1 | 2007 | 6 | 0.290 |
Why?
|
Lymphoproliferative Disorders | 2 | 2023 | 19 | 0.290 |
Why?
|
Recurrence | 6 | 2020 | 355 | 0.280 |
Why?
|
Epstein-Barr Virus Infections | 2 | 2023 | 19 | 0.280 |
Why?
|
Brain Neoplasms | 2 | 2006 | 134 | 0.270 |
Why?
|
Purpura, Thrombotic Thrombocytopenic | 1 | 2006 | 11 | 0.270 |
Why?
|
Drug Administration Schedule | 6 | 2019 | 232 | 0.260 |
Why?
|
Combined Modality Therapy | 4 | 2019 | 379 | 0.250 |
Why?
|
Biomarkers | 3 | 2019 | 704 | 0.240 |
Why?
|
Immunotherapy | 2 | 2008 | 66 | 0.240 |
Why?
|
Prognosis | 6 | 2021 | 874 | 0.240 |
Why?
|
Lymphomatoid Granulomatosis | 1 | 2003 | 3 | 0.230 |
Why?
|
HIV Infections | 2 | 2021 | 997 | 0.230 |
Why?
|
Lymphoma, B-Cell | 3 | 2008 | 10 | 0.220 |
Why?
|
Proto-Oncogene Proteins c-myc | 2 | 2021 | 21 | 0.210 |
Why?
|
Remission Induction | 6 | 2015 | 103 | 0.200 |
Why?
|
Granulocyte-Macrophage Colony-Stimulating Factor | 3 | 2011 | 22 | 0.190 |
Why?
|
Drug Resistance, Neoplasm | 3 | 2020 | 77 | 0.190 |
Why?
|
Thrombosis | 1 | 2021 | 59 | 0.180 |
Why?
|
Deubiquitinating Enzymes | 1 | 2020 | 2 | 0.180 |
Why?
|
Benzylidene Compounds | 1 | 2020 | 2 | 0.180 |
Why?
|
Azepines | 1 | 2020 | 7 | 0.180 |
Why?
|
Retrospective Studies | 5 | 2023 | 3325 | 0.180 |
Why?
|
Multiple Myeloma | 1 | 2020 | 30 | 0.170 |
Why?
|
Graft vs Host Disease | 1 | 2020 | 47 | 0.170 |
Why?
|
Folic Acid Deficiency | 1 | 2019 | 6 | 0.170 |
Why?
|
Phthalazines | 1 | 2019 | 8 | 0.170 |
Why?
|
Young Adult | 4 | 2021 | 1969 | 0.170 |
Why?
|
Respiratory Insufficiency | 1 | 2020 | 50 | 0.170 |
Why?
|
Central Nervous System | 3 | 2023 | 56 | 0.170 |
Why?
|
Proportional Hazards Models | 2 | 2017 | 346 | 0.170 |
Why?
|
Hematopoietic Stem Cell Transplantation | 1 | 2020 | 92 | 0.170 |
Why?
|
Proto-Oncogene Proteins c-bcl-2 | 1 | 2019 | 30 | 0.170 |
Why?
|
Neutropenia | 4 | 2012 | 21 | 0.160 |
Why?
|
Piperazines | 1 | 2019 | 93 | 0.160 |
Why?
|
Cytosine | 2 | 2021 | 6 | 0.160 |
Why?
|
Neoplasm Recurrence, Local | 3 | 2021 | 200 | 0.150 |
Why?
|
Medical Oncology | 1 | 2018 | 36 | 0.150 |
Why?
|
Kidney Diseases | 1 | 2019 | 117 | 0.150 |
Why?
|
Cardiology | 1 | 2018 | 73 | 0.150 |
Why?
|
Immunity | 1 | 2017 | 24 | 0.140 |
Why?
|
Bendamustine Hydrochloride | 1 | 2016 | 4 | 0.140 |
Why?
|
Immunocompromised Host | 1 | 2017 | 45 | 0.140 |
Why?
|
Stroke Volume | 1 | 2016 | 61 | 0.140 |
Why?
|
Biopsy | 2 | 2019 | 239 | 0.130 |
Why?
|
Registries | 1 | 2017 | 191 | 0.130 |
Why?
|
Feasibility Studies | 2 | 2019 | 230 | 0.130 |
Why?
|
Induction Chemotherapy | 1 | 2015 | 14 | 0.130 |
Why?
|
Hematologic Neoplasms | 1 | 2014 | 17 | 0.120 |
Why?
|
Myelodysplastic Syndromes | 2 | 2004 | 38 | 0.120 |
Why?
|
Metabolic Syndrome | 1 | 2014 | 68 | 0.110 |
Why?
|
Leukopenia | 2 | 2011 | 9 | 0.110 |
Why?
|
Lymphoma, Follicular | 2 | 2011 | 4 | 0.110 |
Why?
|
Herpesvirus 4, Human | 2 | 2023 | 14 | 0.110 |
Why?
|
Methotrexate | 2 | 2023 | 42 | 0.110 |
Why?
|
Transcription Factors | 2 | 2004 | 166 | 0.110 |
Why?
|
Cytarabine | 3 | 2023 | 10 | 0.110 |
Why?
|
Daunorubicin | 2 | 2015 | 5 | 0.110 |
Why?
|
DNA-Binding Proteins | 2 | 2004 | 263 | 0.100 |
Why?
|
Transcriptome | 1 | 2012 | 84 | 0.100 |
Why?
|
Hemoglobinuria, Paroxysmal | 1 | 2012 | 7 | 0.100 |
Why?
|
Diabetes Mellitus, Type 2 | 1 | 2014 | 201 | 0.100 |
Why?
|
Obesity | 1 | 2014 | 290 | 0.100 |
Why?
|
Agranulocytosis | 1 | 2011 | 5 | 0.100 |
Why?
|
Yttrium Radioisotopes | 1 | 2011 | 5 | 0.100 |
Why?
|
Lymphoma, B-Cell, Marginal Zone | 1 | 2011 | 6 | 0.100 |
Why?
|
Fatal Outcome | 2 | 2008 | 60 | 0.100 |
Why?
|
Retreatment | 1 | 2010 | 14 | 0.090 |
Why?
|
Salvage Therapy | 1 | 2010 | 36 | 0.090 |
Why?
|
Cytokines | 1 | 2012 | 350 | 0.090 |
Why?
|
Pilot Projects | 1 | 2011 | 403 | 0.090 |
Why?
|
Platelet Count | 2 | 2007 | 22 | 0.090 |
Why?
|
Infusions, Intravenous | 2 | 2020 | 78 | 0.070 |
Why?
|
Weight Loss | 2 | 2019 | 101 | 0.070 |
Why?
|
Tretinoin | 1 | 2007 | 15 | 0.070 |
Why?
|
Tomography, X-Ray Computed | 1 | 2011 | 778 | 0.070 |
Why?
|
Injections, Spinal | 1 | 2007 | 53 | 0.070 |
Why?
|
Vascular Neoplasms | 1 | 2006 | 3 | 0.070 |
Why?
|
ADAMTS13 Protein | 1 | 2006 | 5 | 0.070 |
Why?
|
Follow-Up Studies | 1 | 2011 | 1859 | 0.070 |
Why?
|
Plasma Exchange | 1 | 2006 | 15 | 0.070 |
Why?
|
Severity of Illness Index | 2 | 2021 | 1126 | 0.070 |
Why?
|
ADAM Proteins | 1 | 2006 | 65 | 0.070 |
Why?
|
Immunosuppressive Agents | 2 | 2023 | 135 | 0.060 |
Why?
|
Hemoglobins | 1 | 2006 | 83 | 0.060 |
Why?
|
Autoantibodies | 1 | 2006 | 103 | 0.060 |
Why?
|
Twins, Dizygotic | 1 | 2005 | 4 | 0.060 |
Why?
|
Survival Analysis | 2 | 2019 | 310 | 0.060 |
Why?
|
Radiography | 1 | 2007 | 678 | 0.060 |
Why?
|
Proto-Oncogenes | 1 | 2004 | 4 | 0.060 |
Why?
|
Kidney Transplantation | 1 | 2006 | 126 | 0.060 |
Why?
|
Thalidomide | 1 | 2004 | 7 | 0.060 |
Why?
|
Cohort Studies | 2 | 2021 | 1953 | 0.060 |
Why?
|
United States | 2 | 2021 | 2346 | 0.060 |
Why?
|
Etoposide | 2 | 2019 | 50 | 0.060 |
Why?
|
Peripheral Blood Stem Cell Transplantation | 1 | 2004 | 3 | 0.060 |
Why?
|
Antigens, CD20 | 1 | 2003 | 5 | 0.060 |
Why?
|
Epilepsy, Tonic-Clonic | 1 | 2003 | 9 | 0.060 |
Why?
|
Vision Disorders | 1 | 2003 | 24 | 0.060 |
Why?
|
Antigens, Neoplasm | 1 | 2003 | 44 | 0.060 |
Why?
|
Cyclin D1 | 1 | 2003 | 5 | 0.060 |
Why?
|
Cell Cycle Proteins | 1 | 2003 | 17 | 0.060 |
Why?
|
K562 Cells | 1 | 2003 | 6 | 0.060 |
Why?
|
Telomerase | 1 | 2003 | 10 | 0.060 |
Why?
|
Histones | 1 | 2003 | 28 | 0.060 |
Why?
|
Bridged Bicyclo Compounds, Heterocyclic | 1 | 2022 | 1 | 0.050 |
Why?
|
Voriconazole | 1 | 2022 | 8 | 0.050 |
Why?
|
Apoptosis | 1 | 2003 | 259 | 0.050 |
Why?
|
Cerebral Cortex | 1 | 2003 | 197 | 0.050 |
Why?
|
Sulfonamides | 1 | 2022 | 59 | 0.050 |
Why?
|
Azacitidine | 1 | 2021 | 12 | 0.050 |
Why?
|
United Kingdom | 1 | 2021 | 51 | 0.050 |
Why?
|
Risk Factors | 2 | 2005 | 2467 | 0.050 |
Why?
|
L-Lactate Dehydrogenase | 1 | 2021 | 8 | 0.050 |
Why?
|
Gene Rearrangement | 1 | 2021 | 11 | 0.050 |
Why?
|
Incidence | 1 | 2023 | 759 | 0.050 |
Why?
|
Thrombocytopenia | 2 | 2012 | 31 | 0.040 |
Why?
|
Postoperative Complications | 1 | 2006 | 957 | 0.040 |
Why?
|
Activities of Daily Living | 1 | 2023 | 507 | 0.040 |
Why?
|
Folic Acid | 1 | 2019 | 16 | 0.040 |
Why?
|
Monoclonal Gammopathy of Undetermined Significance | 1 | 2019 | 2 | 0.040 |
Why?
|
Kidney Function Tests | 1 | 2019 | 23 | 0.040 |
Why?
|
Maintenance Chemotherapy | 1 | 2019 | 1 | 0.040 |
Why?
|
Translocation, Genetic | 1 | 2019 | 9 | 0.040 |
Why?
|
Immunoglobulin A | 1 | 2019 | 19 | 0.040 |
Why?
|
Maximum Tolerated Dose | 1 | 2019 | 20 | 0.040 |
Why?
|
Symptom Assessment | 1 | 2019 | 21 | 0.040 |
Why?
|
Transplantation, Homologous | 1 | 2020 | 279 | 0.040 |
Why?
|
Vidarabine | 2 | 2011 | 11 | 0.040 |
Why?
|
Anemia | 2 | 2012 | 99 | 0.040 |
Why?
|
Body Composition | 1 | 2019 | 57 | 0.040 |
Why?
|
Ovarian Neoplasms | 1 | 2019 | 49 | 0.040 |
Why?
|
Sarcopenia | 1 | 2019 | 26 | 0.040 |
Why?
|
Mitoxantrone | 2 | 2011 | 5 | 0.040 |
Why?
|
Interdisciplinary Communication | 1 | 2018 | 28 | 0.040 |
Why?
|
Cardiologists | 1 | 2018 | 14 | 0.040 |
Why?
|
Magnetic Resonance Imaging | 1 | 2003 | 1247 | 0.040 |
Why?
|
Lung Neoplasms | 1 | 2003 | 636 | 0.040 |
Why?
|
Disease Management | 1 | 2019 | 122 | 0.040 |
Why?
|
Bortezomib | 1 | 2017 | 5 | 0.040 |
Why?
|
Sex Factors | 1 | 2019 | 498 | 0.040 |
Why?
|
Tomography, Emission-Computed | 2 | 2006 | 11 | 0.030 |
Why?
|
Prospective Studies | 2 | 2015 | 1824 | 0.030 |
Why?
|
Disease Progression | 2 | 2012 | 812 | 0.030 |
Why?
|
Neoplasms | 1 | 2019 | 257 | 0.030 |
Why?
|
Recombinant Proteins | 2 | 2008 | 258 | 0.030 |
Why?
|
Naphthalimides | 1 | 2015 | 2 | 0.030 |
Why?
|
Adenine | 1 | 2015 | 4 | 0.030 |
Why?
|
Organophosphonates | 1 | 2015 | 5 | 0.030 |
Why?
|
Adolescent | 1 | 2021 | 2334 | 0.030 |
Why?
|
Lipid Metabolism | 1 | 2014 | 31 | 0.030 |
Why?
|
Sensitivity and Specificity | 2 | 2006 | 558 | 0.030 |
Why?
|
Insulin Resistance | 1 | 2014 | 61 | 0.030 |
Why?
|
Reverse Transcriptase Polymerase Chain Reaction | 2 | 2004 | 155 | 0.030 |
Why?
|
Cytogenetic Analysis | 1 | 2012 | 6 | 0.030 |
Why?
|
RNA, Messenger | 2 | 2003 | 325 | 0.030 |
Why?
|
Administration, Oral | 1 | 2012 | 144 | 0.030 |
Why?
|
Signal Transduction | 1 | 2014 | 491 | 0.030 |
Why?
|
Pneumonia | 1 | 2012 | 67 | 0.030 |
Why?
|
Radiopharmaceuticals | 1 | 2011 | 53 | 0.020 |
Why?
|
Time Factors | 1 | 2015 | 1641 | 0.020 |
Why?
|
Nausea | 1 | 2007 | 28 | 0.020 |
Why?
|
Creatinine | 1 | 2007 | 44 | 0.020 |
Why?
|
Methylprednisolone | 1 | 2007 | 24 | 0.020 |
Why?
|
Cisplatin | 1 | 2007 | 92 | 0.020 |
Why?
|
Animals | 1 | 2014 | 4639 | 0.020 |
Why?
|
Dose-Response Relationship, Drug | 1 | 2006 | 456 | 0.020 |
Why?
|
MDS1 and EVI1 Complex Locus Protein | 1 | 2004 | 3 | 0.020 |
Why?
|
Zinc Fingers | 1 | 2004 | 10 | 0.020 |
Why?
|
Cell Lineage | 1 | 2004 | 31 | 0.020 |
Why?
|
Spleen | 1 | 2004 | 54 | 0.010 |
Why?
|
Teniposide | 1 | 2004 | 2 | 0.010 |
Why?
|
Bleomycin | 1 | 2004 | 2 | 0.010 |
Why?
|
Neoplasm Staging | 1 | 2005 | 364 | 0.010 |
Why?
|
Drug Therapy, Combination | 1 | 2004 | 245 | 0.010 |
Why?
|
Interferon-alpha | 1 | 2004 | 69 | 0.010 |
Why?
|
S Phase | 1 | 2003 | 10 | 0.010 |
Why?
|
E2F Transcription Factors | 1 | 2003 | 5 | 0.010 |
Why?
|
E2F1 Transcription Factor | 1 | 2003 | 5 | 0.010 |
Why?
|
Retinoblastoma Protein | 1 | 2003 | 10 | 0.010 |
Why?
|
Transplantation, Autologous | 1 | 2004 | 197 | 0.010 |
Why?
|
Patient Selection | 1 | 2005 | 234 | 0.010 |
Why?
|
Karyotyping | 1 | 2003 | 11 | 0.010 |
Why?
|
Granulocytes | 1 | 2003 | 23 | 0.010 |
Why?
|
DNA Primers | 1 | 2003 | 54 | 0.010 |
Why?
|
In Situ Hybridization, Fluorescence | 1 | 2003 | 32 | 0.010 |
Why?
|
Bone Marrow Cells | 1 | 2003 | 58 | 0.010 |
Why?
|
Cell Nucleus | 1 | 2003 | 80 | 0.010 |
Why?
|
Transcription, Genetic | 1 | 2003 | 108 | 0.010 |
Why?
|
Blotting, Western | 1 | 2003 | 175 | 0.010 |
Why?
|
Polymerase Chain Reaction | 1 | 2003 | 166 | 0.010 |
Why?
|
Bone Marrow | 1 | 2003 | 78 | 0.010 |
Why?
|
Acute Disease | 1 | 2003 | 225 | 0.010 |
Why?
|
Immunohistochemistry | 1 | 2003 | 411 | 0.010 |
Why?
|